Vasopressin and splanchnic shunting. A quantitative comparison

Area of Science:

• Cardiovascular Physiology
• Hepatology

Background:

• Vasopressin is used to manage portal hypertension.
• Its systemic and splanchnic hemodynamic effects require further elucidation.
• Comparison with surgical shunting is needed.

Purpose of the Study:

• To analyze splanchnic and systemic effects of vasopressin.
• To measure vasopressin's portal pressure-lowering efficacy versus shunting.
• To identify factors predicting vasopressin's adverse cardiac effects.

Main Methods:

• Intraoperative measurements of cardiac output and pressures in 30 patients undergoing shunts.
• Administration of vasopressin and nitroprusside infusions.
• Analysis of vasopressin's efficacy relative to shunt procedures.

Main Results:

• Vasopressin significantly increased systemic vascular resistance and pulmonary capillary wedge pressure.
• Overall cardiac index reduction was insignificant, but 10 patients showed >20% decrease.
• Vasopressin was 38% as effective as shunting for splanchnic venous pressure reduction.
• Nitroprusside reversed vasopressin-induced cardiac output depression.
• Vasopressin's portal hypotensive effect predicted shunt efficacy.

Conclusions:

• Vasopressin has significant systemic vasoconstrictive effects and can cause substantial cardiac output depression in susceptible individuals.
• Vasopressin is less effective than shunting in reducing portal pressure.
• Nitroprusside can mitigate vasopressin's adverse cardiac effects.
• Vasopressin's portal pressure reduction may predict shunt success.